FDA Grants Soligenix Orphan Drug Designation for Dusquetide in Behçet's Disease Treatment
核心洞察
The FDA has granted orphan drug designation to dusquetide (SGX945) for treating Behçet's Disease (搜索), providing seven years of market exclusivity upon approval.
Phase 2a clinical results showed SGX945 achieved 40% improvement in ulcer reduction compared to 37% for the only approved drug apremilast.
The designation addresses a significant unmet medical need for up to 18,000 U.S. patients and 1 million worldwide affected by this incurable autoimmune disease.
Soligenix has received orphan drug designation from the FDA for dusquetide, the active ingredient in SGX945, for the treatment of Behçet's Disease (搜索). The designation follows positive Phase 2a clinical results demonstrating biological efficacy and safety in patients with this rare autoimmune condition that affects up to 18,000 people in the United States and as many as 1 million worldwide.
The orphan drug designation provides SGX945 with seven years of U.S. market exclusivity upon FDA approval, along with access to government grants for clinical trials, waiver of expensive FDA user fees, and certain tax credits. This regulatory milestone represents a significant advancement for patients suffering from Behçet's Disease (搜索), where limited treatment options exist.
Phase 2a Study Results Show Promise
The Phase 2a pilot study enrolled 8 patients with Behçet's Disease (搜索) in an open-label design comparable to the Phase 3 study that supported apremilast's marketing approval. Using the same primary endpoint of area under the curve (AUC) of mean number of ulcers versus time, SGX945 demonstrated a 40% improvement relative to the historical placebo group after 4 weeks of treatment, compared to apremilast's 37% improvement.
Notably, the improvement with SGX945 was sustained throughout the 4-week follow-up period after treatment cessation, showing 32% improvement at Week 8 despite stopping treatment at Week 4. In contrast, apremilast, which was administered continuously through Week 12, showed 41% improvement at Week 8.
One patient who began the study with a punctuated skin ulcer experienced complete resolution during the 4-week SGX945 treatment period. Skin ulcers are generally considered very difficult to resolve and typically require protracted treatment, making this result particularly noteworthy.
Superior Safety Profile
SGX945 demonstrated excellent tolerability with no treatment-related adverse events reported in the Phase 2a study. This safety profile contrasts favorably with apremilast, where common adverse events include diarrhea (41% of patients), nausea (19% of patients), and headache (14% of patients). None of these side effects were observed with SGX945 treatment.
"Given the clinically meaningful improvements seen in a Phase 2 proof-of-concept study in patients with oral aphthous ulcers due to Behçet's Disease (搜索), we are hopeful dusquetide will have a role to play in helping underserved patients suffering from this difficult to treat and chronic auto-immune disease," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix.
Addressing Unmet Medical Need
Behçet's Disease (搜索) is an inflammatory disorder of blood vessels (vasculitis (搜索)) that commonly affects young adults. The disease presents with mouth sores in approximately 95% of patients, skin rashes and lesions in 50%, genital sores in 50%, leg ulcers in 40%, and eye inflammation in 15% of patients. The condition significantly impacts quality of life and patients' ability to engage in productive activities.
Currently, there is no cure for Behçet's Disease (搜索), and treatments focus on symptom management. Corticosteroids are frequently used but have limited long-term efficacy and significant side effects with chronic use. Immunosuppressive drugs carry risks of infection, liver and kidney problems, low blood counts, and high blood pressure. Apremilast remains the only approved drug specifically for Behçet's Disease, used as maintenance therapy to prevent oral ulcer formation, but requires continuous administration and is associated with high costs and notable side effects.
Novel Mechanism of Action
Dusquetide belongs to a new class of short, synthetic peptides called innate defense regulators (IDRs). It modulates the body's reaction to injury and infection toward an anti-inflammatory, anti-infective, and tissue healing response. While IDRs have no direct antibiotic activity, they increase survival after infections by modulating host innate immune system (搜索) responses and accelerate resolution of tissue damage from various causes including bacterial pathogens, trauma, and chemo- or radiation therapy.
The compound has demonstrated safety and tolerability in a Phase 1 clinical study involving 84 healthy volunteers and showed positive efficacy results in Phase 2 and 3 studies with over 350 subjects with oral mucositis (搜索) due to chemoradiation therapy for head and neck cancer.
Regulatory Pathway Forward
SGX945 previously received Fast Track designation from the FDA for treating oral lesions of Behçet's Disease (搜索) in January 2024. This designation facilitates development and expedites review of drugs addressing serious conditions with unmet medical needs. Fast Track designation allows for rolling NDA submissions and typically qualifies for priority review with an abbreviated six-month review timeline.
Soligenix maintains a strong intellectual property position in the IDR technology platform, including composition of matter for dusquetide and related analogs. The compound was developed based on discoveries by Professors B. Brett Finlay, PhD and Robert Hancock, PhD of the University of British Columbia, Canada.